{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:24:06Z","timestamp":1781706246753,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RTG 2535"],"award-info":[{"award-number":["RTG 2535"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ejca.2023.112957","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T19:34:18Z","timestamp":1687462458000},"page":"112957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study"],"prefix":"10.1016","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8279-9239","authenticated-orcid":false,"given":"Georg C.","family":"Lodde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena M.","family":"Wulfken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"K\u00e4hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Loquai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svea","family":"H\u00fcning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Glutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Nikfarjam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Erdmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina L.","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Stang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Kowall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Galetzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Roesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2023.112957_bib1","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"22","key":"10.1016\/j.ejca.2023.112957_bib2","first-page":"2543","article-title":"Prognosis of patients with stage III melanoma according to American joint committee on cancer version 8: a reassessment on the basis of 3 independent stage III melanoma cohorts","volume":"38","author":"Garbe","year":"2020","journal-title":"J\u00a0Clin\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.112957_bib3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2019.06.011","article-title":"Impact of American joint committee on cancer 8th edition classification on staging and survival of patients with melanoma","volume":"119","author":"Kanaki","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.112957_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejca.2019.05.020","article-title":"Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325\/KEYNOTE-054 trial of pembrolizumab versus placebo in resected high-risk stage III melanoma","volume":"116","author":"Eggermont","year":"2019","journal-title":"Eur J Cancer"},{"issue":"35","key":"10.1016\/j.ejca.2023.112957_bib5","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.18.01219","article-title":"Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma","volume":"36","author":"Hauschild","year":"2018","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2023.112957_bib6","first-page":"1789","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N\u00a0Engl\u00a0J\u00a0Med"},{"issue":"19","key":"10.1016\/j.ejca.2023.112957_bib7","first-page":"1813","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl\u00a0J\u00a0Med"},{"issue":"19","key":"10.1016\/j.ejca.2023.112957_bib8","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2023.112957_bib9","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.ejca.2023.112957_bib10","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-22-3145","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-Year efficacy and biomarker results from CheckMate 238","author":"Larkin","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2023.112957_bib11","first-page":"1139","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N\u00a0Engl\u00a0J\u00a0Med"},{"issue":"10","key":"10.1016\/j.ejca.2023.112957_bib12","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.3390\/cancers13102319","article-title":"Factors influencing the adjuvant therapy decision: results of a real-world multicenter data analysis of 904 melanoma patients","volume":"13","author":"Lodde","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.ejca.2023.112957_bib13","doi-asserted-by":"crossref","DOI":"10.5867\/medwave.2019.11.7748","article-title":"General concepts in biostatistics and clinical epidemiology: observational studies with cohort design","volume":"19","author":"Lazcano G","year":"2019","journal-title":"Medwave"},{"issue":"11","key":"10.1016\/j.ejca.2023.112957_bib14","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"4","key":"10.1016\/j.ejca.2023.112957_bib15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/1740774515586176","article-title":"Measures of follow-up in time-to-event studies: why provide them and what should they be?","volume":"12","author":"Betensky","year":"2015","journal-title":"Clin Trials"},{"issue":"4","key":"10.1016\/j.ejca.2023.112957_bib16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10654-010-9440-x","article-title":"The ongoing tyranny of statistical significance testing in biomedical research","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"7280","key":"10.1016\/j.ejca.2023.112957_bib17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/bmj.322.7280.226","article-title":"Sifting the evidence\u2014what's wrong with significance tests? Another comment on the role of statistical methods","volume":"322","author":"Sterne","year":"2001","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejca.2023.112957_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/01.ede.0000249522.75868.16","article-title":"Heuristic thinking and inference from observational epidemiology","volume":"18","author":"Lash","year":"2007","journal-title":"Epidemiology"},{"issue":"1","key":"10.1016\/j.ejca.2023.112957_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cmpb.2003.10.004","article-title":"Adjusted survival curves with inverse probability weights","volume":"75","author":"Cole","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"issue":"1","key":"10.1016\/j.ejca.2023.112957_bib20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"1","key":"10.1016\/j.ejca.2023.112957_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The hazards of hazard ratios","volume":"21","author":"Hern\u00e1n","year":"2010","journal-title":"Epidemiology"},{"key":"10.1016\/j.ejca.2023.112957_bib22","unstructured":"Therneau, T.M.A package for survival analysis in R. 2022."},{"key":"10.1016\/j.ejca.2023.112957_bib23","series-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"issue":"3","key":"10.1016\/j.ejca.2023.112957_bib24","first-page":"574","article-title":"Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis","volume":"124","author":"Bhave","year":"2021","journal-title":"Br\u00a0J\u00a0Cancer"},{"issue":"13","key":"10.1016\/j.ejca.2023.112957_bib25","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1245\/s10434-020-08631-2","article-title":"Adjuvant therapy failure patterns in the modern era of melanoma management","volume":"27","author":"Rauwerdink","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2023.112957_bib26","first-page":"234","article-title":"Adjuvant treatment for melanoma in clinical practice \u2013 trial versus reality","volume":"158","author":"de Meza","year":"2021","journal-title":"Eur\u00a0J\u00a0Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2023.112957_bib27","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.annonc.2020.04.471","article-title":"Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy(\u2606).","volume":"31","author":"Owen","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.112957_bib28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejca.2022.06.041","article-title":"Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria","volume":"173","author":"Larkin","year":"2022","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2023.112957_bib29","first-page":"1026","article-title":"Tumour mutation status and sites of metastasis in patients with cutaneous melanoma","volume":"117","author":"Adler","year":"2017","journal-title":"Br\u00a0J\u00a0Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2023.112957_bib30","first-page":"186","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial\u2014ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J\u00a0Clin\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.112957_bib31","unstructured":"Deutsche Krebsgesellschaft, D.K. and AWMF, Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Melanoms, Langversion 3.3, 2020, AWMF Registernummer: 032\/024OL. 2020."},{"issue":"15_suppl","key":"10.1016\/j.ejca.2023.112957_bib32","first-page":"9502","article-title":"Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III\/IV melanoma: updated results from a phase III trial (CheckMate 238)","volume":"36","author":"Weber","year":"2018","journal-title":"J\u00a0Clin\u00a0Oncol"},{"issue":"33","key":"10.1016\/j.ejca.2023.112957_bib33","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2023.112957_bib34","first-page":"1186","article-title":"Adjuvant anti-PD-1 antibody treatment in stage III\/IV melanoma: real-world experience and health economic considerations","volume":"19","author":"Koelblinger","year":"2021","journal-title":"JDDG: J\u00a0Dtsch\u00a0Dermatol\u00a0Ges"},{"key":"10.1016\/j.ejca.2023.112957_bib35","unstructured":"Eggermont, A.M.M., et al., Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma. NEJM evidence. 0(0): p. EVIDoa2200214."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300309X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300309X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:33Z","timestamp":1760733693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492300309X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":35,"alternative-id":["S095980492300309X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.112957","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.112957","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112957"}}